Cited by 711Menopause: Health Impacts and TreatmentsCardiac Imaging and DiagnosticsEstrogen and related hormone effects

Estrogen Therapy and Coronary-Artery Calcification

Open access
Manson, JoAnn E., Allison, Matthew A., Rossouw, Jacques E., Carr, J. Jeffrey, Langer, Robert D., Hsia, Judith, Kuller, Lewis H., Cochrane, Barbara B. +10 more·2007·New England Journal of Medicine

Abstract

BACKGROUND: Calcified plaque in the coronary arteries is a marker for atheromatous-plaque burden and is predictive of future risk of cardiovascular events. We examined the relationship between estrogen therapy and coronary-artery calcium in the context of a randomized clinical trial. METHODS: In our ancillary substudy of the Women's Health Initiative trial of conjugated equine estrogens (0.625 mg per day) as compared with placebo in women who had undergone hysterectomy, we performed computed tomography of the heart in 1064 women aged 50 to 59 years at randomization. Imaging was conducted at 28 of 40 centers after a mean of 7.4 years of treatment and 1.3 years after the trial was completed (8.7 years after randomization). Coronary-artery calcium (or Agatston) scores were measured at a central reading center without knowledge of randomization status. RESULTS: The mean coronary-artery calcium score after trial completion was lower among women receiving estrogen (83.1) than among those receiving placebo (123.1) (P=0.02 by rank test). After adjustment for coronary risk factors, the multivariate odds ratios for coronary-artery calcium scores of more than 0, 10 or more, and 100 or more in the group receiving estrogen as compared with placebo were 0.78 (95% confidence interval, 0.58 to 1.04), 0.74 (0.55 to 0.99), and 0.69 (0.48 to 0.98), respectively. The corresponding odds ratios among women with at least 80% adherence to the study estrogen or placebo were 0.64 (P=0.01), 0.55 (P<0.001), and 0.46 (P=0.001). For coronary-artery calcium scores of more than 300 (vs. <10), the multivariate odds ratio was 0.58 (P=0.03) in an intention-to-treat analysis and 0.39 (P=0.004) among women with at least 80% adherence. CONCLUSIONS: Among women 50 to 59 years old at enrollment, the calcified-plaque burden in the coronary arteries after trial completion was lower in women assigned to estrogen than in those assigned to placebo. However, estrogen has complex biologic effects and may influence the risk of cardiovascular events and other outcomes through multiple pathways. (ClinicalTrials.gov number, NCT00000611.)

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa071513

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Subsequent analyses of WHI data showed no increase in cardiovascular disease in women starting treatment within 10 years of menopause.

    “Subsequent analyses of these data showed no increase in cardiovascular disease in women starting treatment within 10 years of menopause [82].”

    From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [82]

    The Abstract reports that secondary WHI analyses found no increased risk of coronary heart disease among women aged 50–59 receiving estrogen, and the Discussion says the findings offer some reassurance about coronary events in women recently past menopause. But the paper does not establish the claim for women specifically starting treatment within 10 years of menopause or for cardiovascular disease broadly; it also reports an increased stroke risk in the estrogen trial. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 7

  1. [2]2. Mendelsohn ME, Karas RH. The pro- tective effects of estrogen on the cardio- vascular system. N Engl J Med 1999;340: 1801-11.
  2. [10]10. cil on Cardiovascular Radiology and In- tervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation 2006;114:1761-91.
  3. [14]14. The New England Journal of Medicine . For personal use only. No other uses without permission. Copyright © 2007 Massachusetts Medical Society. All rights reserved. n engl j med 356;25
  4. [25]25. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery cal- cium using ultrafast computed tomogra- phy. J Am Coll Cardiol 1990;15:827-32.
  5. [33]33. questions and the case for new clinical trials. Menopause 2006;13:139-47.
  6. [35]35. Chae CU, Manson JE. Postmenopaus- al hormone therapy. In: Manson JE, Bur- ing JE, Ridker PM, Gaziano JM, eds. Clin- ical trials in heart disease. Philadelphia: Saunders/Elsevier, 2004:349-63.
  7. [37]37. Phillips LD, Langer RD. Postmeno- pausal hormone therapy: critical reap- praisal and a unified hypothesis. Fertil Steril 2005;83:558-66.

Cited by

Sorted by citations

Authors
Manson, J. E., Allison, M. A., Rossouw, J. E., Carr, J. J., Langer, R. D., Hsia, J., Kuller, L. H., Cochrane, B. B., Hunt, J. R., Ludlam, S. E., Pettinger, M. B., Gass, M., Margolis, K. L., Nathan, L., Ockene, J. K., Prentice, R. L., Robbins, J., & Stefanick, M. L.
Affiliations
  • Brigham and Women's Hospital (US)
  • University of California San Diego (US)
  • National Institutes of Health (US)
  • Wake Forest University Health Sciences (US)
  • Geisinger Health System (US)
  • George Washington University (US)
  • University of Pittsburgh (US)
  • University of Washington (US)
  • Fred Hutch Cancer Center (US)
  • University of Cincinnati (US)
  • University of Minnesota (US)
  • University of California, Los Angeles (US)
  • University of Massachusetts Chan Medical School (US)
  • University of California, Davis (US)
  • Stanford University (US)
Venue
New England Journal of Medicine
Published
2007-06-21
Volume
356
Issue
25
Pages
2591-2602
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2110885050
Cited by
711
References
38
Citations by year
2026: 14 · 2025: 11 · 2024: 12 · 2023: 17 · 2022: 16 · 2021: 19 · 2020: 24 · 2019: 19 · 2018: 25 · 2017: 27 · 2016: 26 · 2015: 37 · 2014: 35 · 2013: 50 · 2012: 42
FWCI
69.19
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • eScholarship@UMassChan (submittedVersion)
Funders
  • Massachusetts Medical Society
  • National Heart, Lung, and Blood Institute
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiac Imaging and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
Keywords
estrogen therapy, coronary artery calcification, conjugated equine estrogens, Women's Health Initiative, coronary artery calcium score, postmenopausal women, hysterectomy, cardiovascular risk, medication adherence, coronary risk factors, cardiovascular disease prevention, hormone replacement therapy, coronary heart disease prevention
MeSH terms
Calcinosis, Coronary Disease, Estrogens, Conjugated (USP), Female, Humans, Hysterectomy, Middle Aged, Risk Factors, Tomography, X-Ray Computed, Estrogen Replacement Therapy, Multivariate Analysis, Logistic Models, Odds Ratio, Coronary Angiography, Postmenopause

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review